Rapid Micro Biosystems given contract for rapid sterility testing

The Biomedical Advanced Research and Development Authority has signed a contract with Rapid Micro Biosystems, a provider of automated, non-destructive, rapid microbial detection systems, to develop a method of rapid sterility testing for vaccines.

The contract is part of the Innovative Technologies Program of BARDA’s Strategic Science and Technology Division. Under the contract’s terms, Rapid Micro Biosystems will be paid $2.2 million for the first year of the contract, with an additional $4.5 million if the contract is extend for the following two years, according to

“We are pleased to be awarded this contract by BARDA”, Steve Delity, chief executive officer of Rapid Micro Biosystems, said, reports. “Rapid Micro is the leader in automated rapid detection, and we look forward to working closely with BARDA to develop a solution to help with pandemic response.”

It is believed that if microbiological quality control testing is conducted faster, the release cycle of vaccines can be reduced by between two to four weeks. A shorter release time for vaccines and countermeasures would lead to better chances to prevent and control a disease outbreak or the effects of a biological attack.

Rapid Micro Biosystems, headquartered in Bedford, Massachusetts, was founded in 2006. The company was previously known as Genomic Profiling Systems, but changed its name in 2007.